Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Stock Forecast

Stock Price Forecast

The 4 analysts with 12-month price forecasts for Corcept Therapeutics stock have an average target of 143.25, with a low estimate of 131 and a high estimate of 150. The average target predicts an increase of 130.16% from the current stock price of 62.24.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$131	$143.25	$150	$150
Change	+110.48%	+130.16%	+141.00%	+141.00%

Analyst Ratings

The average analyst rating for Corcept Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25
Strong Buy	3	3	3	3	3	3
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Amsellem Piper Sandler	Piper Sandler	Buy Maintains $128 → $131	Buy	Maintains	$128 → $131	+110.48%	Apr 3, 2025
Edward Nash Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $130 → $142	Strong Buy	Maintains	$130 → $142	+128.15%	Apr 1, 2025
Joon Lee Truist Securities	Truist Securities	Strong Buy Maintains $76 → $150	Strong Buy	Maintains	$76 → $150	+141.00%	Mar 31, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $115 → $150	Strong Buy	Maintains	$115 → $150	+141.00%	Mar 31, 2025
David Amsellem Piper Sandler	Piper Sandler	Buy Maintains $67 → $78	Buy	Maintains	$67 → $78	+25.32%	Feb 27, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

923.49M

Increased by 36.81%

from 675.04M

Revenue Next Year

1.22B

Increased by 32.00%

from 923.49M

EPS This Year

1.95

Increased by 58.39%

from 1.23

EPS Next Year

3.61

Increased by 85.47%

from 1.95

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	353.87M	365.98M	401.86M	482.38M	675.04M	923.49M	1.22B	1.66B
Revenue Growth	15.46%	3.42%	9.80%	20.04%	39.94%	36.81%	32.00%	35.77%
EPS	0.85	0.89	0.87	0.94	1.23	1.95	3.61	5.87
EPS Growth	10.39%	4.71%	-2.25%	8.05%	30.85%	58.39%	85.47%	62.31%
Forward PE	-	-	-	-	-	31.95	17.23	10.61
No. Analysts	-	-	-	-	-	6	6	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	971.0M	1.5B	2.0B
Avg	923.5M	1.2B	1.7B
Low	869.3M	1.0B	1.3B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	43.8%	57.1%	64.2%
Avg	36.8%	32.0%	35.8%
Low	28.8%	12.7%	9.0%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	2.27	4.78	7.79
Avg	1.95	3.61	5.87
Low	1.71	2.73	3.50

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	84.4%	145.2%	115.6%
Avg	58.4%	85.5%	62.3%
Low	38.6%	40.3%	-3.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.